Recorpus is a Biotech startup advancing an innovative technology to treat a broad spectrum of chronic diseases, with cancer currently as its primary focus. Working at the crossroads of medicine, biology, physics, and engineering, we challenge established paradigms in chronic disease research and treatment.
After more than a decade of independent research, I have developed a novel therapeutic concept, strategy and technology to recondition the human body to a healthier state. It addresses the root cause of cancer, rather than focusing solely on symptom management or selective cell elimination. This approach shows promise for curing cancers across multiple organs, including advanced stages and metastases, including difficult cases such as pancreatic or ovarian metastases, without requiring surgery or radiotherapy. Beyond oncology, it also holds broader potential for restoring organ health in various chronic conditions and for positively modulating certain aspects of aging.
Recorpus is now seeking seed funding and/or a strategic partner to conduct a decisive preclinical proof-of-concept study within 36 months using a novel treatment technology. Clinical trials are targeted within 3-4 years, potentially fast-tracking relief for patients with cancer in a particular organ (e.g. lung, liver or pancreas) before broader applications.
This is high-potential research grounded in interdisciplinary science. Join us, whether as an investor and/or strategic partner in pushing the boundaries of regenerative medicine. Contact us to learn more or discuss opportunities: info@recorpus.com.